Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices 48103 

In addition to the partnerships above, 

HRSA is seeking comment on state or 

regional initiatives to consider when 

establishing the qualifying standards for 

the CHGME Quality Bonus System, as 

well as suggestions for how to 

distinguish between levels of 

engagement and performance in a 

meaningful way. 

Documentation: To receive a quality 

bonus payment based upon engagement 

in state- or regional-level pediatric 

health care transformation, CHGME 

hospitals would be required to submit a 

letter from the lead organization, which 

could include the project director for a 

HRSA-supported program or the state 

Medicaid Director, confirming 

participation by the children’s hospital 

in the program and delineating the roles 

and responsibilities of the children’s 

hospital in the program activities. In 

addition, CHGME hospitals would be 

required to submit a brief narrative 

statement describing how CHGME 

trainees are integrated into state- or 

regional-level pediatric health care 

transformation activities and the 

expected benefits for trainees and the 

health systems served by the children’s 

hospital. HRSA is seeking comment on 

this proposed approach including 

opportunities to limit burden and 

streamline the documentation to 

determine whether applicants meet 

standards and distinguish among levels 

of engagement and performance. 

Payment Structure: HRSA proposes 

that CHGME hospitals that meet the 

standards receive a portion of the 

available funds for the CHGME Quality 

Bonus System. HRSA proposes a three 

tiered payment structure to recognize 

the different annual payment levels 

received by CHGME hospitals. Hospitals 

that meet the Quality Bonus Systems 

standards will be evenly divided into 

three tiers based on their combined 

direct and indirect fiscal year payment 

amounts, as calculated per the 

established CHGME program formulas: 

Tier 1: Hospitals that qualify for the 

quality bonus payment that are in the 

lowest third among hospitals that 

qualify for the quality bonus payment of 

calculated CHGME annual payments 

will receive a base payment. 

Tier 2: Hospitals that qualify for the 

quality bonus payment that are in the 

middle third will receive two times the 

base payment. 

Tier 3: Hospitals that qualify for the 

quality bonus payment that are in the 

highest third will receive three times the 

base payment. 

The base payment rate would be 

determined from the total amount 

available and the number of hospitals 

that qualify for the CHGME Quality 

Bonus System in a fiscal year. HRSA 

would also seek to recognize the 

hospital’s level of engagement or 

performance in the bonus amount. 

HRSA is also interested in gathering 

views and suggestions on whether any 

of the existing information that 

hospitals already report to the Centers of 

Medicare and Medicaid Services, HRSA, 

accrediting bodies, and others could be 

used to measure the performance of 

GME programs and related health 

outcomes for FY 2019 or subsequent 

years. This could be individual 

measures or combinations of measures 

that are reported to different entities. 

Quality Bonus Payment in FY 2020 and 

Beyond—Areas for Public Comment 

In future years, HRSA will refine the 

CHGME Quality Bonus System to reflect 

the feedback received from 

stakeholders, as well as advancements 

in the development of standardized 

GME quality measures. To that end, 

HRSA also is requesting comments on 

several areas of the Quality Bonus 

System that will be implemented in FY 

2020 and beyond. For long-term 

implementation, HRSA seeks public 

comments on the following areas: 

CHGME Hospital Eligibility: HRSA 

proposes to include all eligible CHGME 

hospitals, including those newly 

qualified, as eligible entities for the 

CHGME Quality Bonus System. 

Quality Bonus System Measures: 

HRSA is seeking comment on 

appropriate GME outcome measures 

that can assess and distinguish 

performance in meaningful ways. HRSA 

is considering several GME outcome 

measures including resident specialty 

outcomes (e.g., number of graduates in 

high need pediatric specialties), resident 

service outcomes (e.g., service to high 

need rural or underserved 

communities), and children’s hospital 

quality outcomes. As noted above, these 

measures could be existing measures 

that hospitals already report or new 

ones that would be developed or 

improved for use in determining quality 

bonuses. 

Data Sources: HRSA is seeking 

comment on available data sources on 

which to base the Quality Bonus 

System. HRSA is requesting comment 

on data sources that are publicly 

available, will streamline reporting 

requirements, and will limit burden on 

CHGME programs. 

Tiering of Quality Bonus Payments: 

HRSA is requesting comments on 

payment structures to recognize 

hospitals according to their level of 

engagement and/or outcomes while also 

taking into account the different size of 

GME programs. The goal is for payment 

structures to recognize the quality of 

hospitals’ programs considering the 

different circumstances in which 

different children’s hospitals operate 

(e.g., patient severity, size of training 

programs, number of specialties trained, 

etc.) 

Frequency of Review: HRSA plans to 

review and update the CHGME Quality 

Bonus System standards regularly to 

reflect changes in GME and advances in 

measuring GME outcomes. 

Dated: October 5, 2017 

George Sigounas, 

Administrator. 

[FR Doc. 2017–22381 Filed 10–13–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Service 

Administration 

Advisory Committee on Heritable 

Disorders in Newborns and Children 

AGENCY: Health Resources and Service 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, notice 

is hereby given that a meeting is 

scheduled for the Advisory Committee 

on Heritable Disorders in Newborns and 

Children (ACHDNC). This meeting will 

be open to the public but advance 

registration is required. Please register 

online at http://

www.achdncmeetings.org/ by 12:00 p.m. 

Eastern Time on November 6, 2017. 

Information about the ACHDNC can be 

obtained by accessing the following 

Web site: https://www.hrsa.gov/ 

advisorycommittees/mchbadvisory/ 

heritabledisorders/index.html. 

DATES: The meeting will be held on 

Wednesday, November 8, 2017, 9:30 

a.m. to 5:00 p.m. Eastern Time and 

Thursday, November 9, 2017, 9:30 a.m. 

to 3:00 p.m. Eastern Time (meeting 

times are tentative). 

ADDRESSES: This meeting will be held 

in-person at 5600 Fishers Lane, 5th 

Floor Pavilion, Rockville, MD 20857. 

The meeting will also be accessible via 

Webcast. Instructions on how to access 

the meeting via Webcast will be 

provided upon registration. Please note, 

the 5600 Fishers Lane building requires 

security screening on entry. Visitors 

must provide a driver’s license, 

passport, or other form of governmentissued photo identification to be granted 

entry into the facility. Non-US Citizens 

planning to attend in person will need 


ethrower on DSK3G9T082PROD with NOTICES
48104 Federal Register / Vol. 82, No. 198 / Monday, October 16, 2017 / Notices 

to provide additional information to 

HRSA by October 24, 2017, 12:00 p.m. 

Eastern Time. Please see contact 

information below. 

FOR FURTHER INFORMATION CONTACT: 

Anyone requesting information 

regarding the ACHDNC should contact 

Ann Ferrero, Maternal and Child Health 

Bureau (MCHB), HRSA, in one of three 

ways: (1) Send a request to the following 

address: Ann Ferrero, MCHB, HRSA 

5600 Fishers Lane, Room 18N100C, 

Rockville, MD 20857; (2) call 301–443– 

3999; or (3) send an email to: AFerrero@

hrsa.gov. 

SUPPLEMENTARY INFORMATION: The 

ACHDNC provides advice to the 

Secretary of HHS on the development of 

newborn screening activities, 

technologies, policies, guidelines, and 

programs for effectively reducing 

morbidity and mortality in newborns 

and children having, or at risk for, 

heritable disorders. In addition, 

ACHDNC’s recommendations regarding 

inclusion of additional conditions and 

inherited disorders for screening which 

have been adopted by the Secretary are 

then included in the Recommended 

Uniform Screening Panel (RUSP). 

Conditions listed on the RUSP 

constitute part of the comprehensive 

preventive health guidelines supported 

by HRSA for infants and children under 

section 2713 of the Public Health 

Service Act, codified at 42 U.S.C. 

300gg–13. Under this provision, nongrandfathered health plans are required 

to cover screenings included in the 

HRSA-supported comprehensive 

guidelines without charging a copayment, co-insurance, or deductible for 

plan years (i.e., policy years) beginning 

on or after the date that is one year from 

the Secretary’s adoption of the 

condition for screening. 

The meeting agenda will include: (1) 

An update on states’ progress toward 

the newborn screening timeliness goals 

outlined by the Committee; (2) a 

presentation on phase 2 of the spinal 

muscular atrophy evidence review; (3) 

presentations on newborn screening 

topics such as the clinical and public 

health impact of Severe Combined 

Immunodeficiency (SCID), carrier status 

in the context of newborn screening, 

and a review of long term follow up in 

newborn screening; and (4) updates 

from the Laboratory Standards and 

Procedures workgroup, Follow-up and 

Treatment workgroup, and Education 

and Training workgroup. The 

Committee will not be voting on a 

proposed addition of a condition to the 

RUSP. Agenda items are subject to 

change. The final meeting agenda will 

be available 2 days prior to the meeting 

on the Committee’s Web site: http://

www.hrsa.gov/advisorycommittees/ 

mchbadvisory/heritabledisorders. 

Members of the public will have the 

opportunity to provide comments. All 

comments are part of the official 

Committee record. To submit written 

comments or request time for an oral 

comment at the meeting, please register 

online by 11:59 p.m. Eastern Time on 

November 2, 2017, at http://

www.achdncmeetings.org/. To ensure 

all individuals who have registered and 

requested time for oral comments are 

accommodated, the allocated time for 

comments may be limited. Individuals 

associated with groups or who plan to 

provide comments on similar topics 

may be asked to combine their 

comments and present them through a 

single representative. No audiovisual 

presentations are permitted. Written 

comments should identify the 

individual’s name, address, email, 

telephone number, professional or 

organization affiliation, background or 

area of expertise (i.e., parent, family 

member, researcher, clinician, public 

health, etc.) and the topic/subject 

matter. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify Ann Ferrero using the address 

and phone number above at least 10 

days prior to the meeting. 

Amy McNulty, 

Acting Director, Division of the Executive 

Secretariat. 

[FR Doc. 2017–22313 Filed 10–13–17; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; NIAID Clinical Trial 

Planning Grant (R34) and Implementation 

Cooperative Agreement (U01). 

Date: November 6–9, 2017. 

Time: 9:00 a.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892, 

(Telephone Conference Call). 

Contact Person: Geetanjali Bansal, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

Room 3G49, National Institutes of Health/ 

NIAID, 5601 Fishers Lane, MSC 9834, 

Bethesda, MD 20892–9834, (240) 669–5073, 

geetanjali.bansal@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 10, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–22259 Filed 10–13–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Translational Studies on Adducts For Cancer 

Risk Identification and Prevention. 

Date: November 8, 2017. 

Time: 1:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W108, Rockville, MD 20850, (Telephone 

Conference Call). 


ethrower on DSK3G9T082PROD with NOTICES